Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CC-1
- Development stage
- Phase 2
- Lead developer
- German Cancer Research Center
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CC-1 is a bispecific T-cell engager (BiTE) that works by simultaneously binding to CD3 on T cells and PSMA (Prostate-specific membrane antigen) on cancer cells. This dual binding redirects T cells to attack PSMA-expressing cancer cells, primarily in prostate cancer. Clinical trials have shown manageable toxicity profiles, with cytokine release syndrome being the most common side effect.
- Other names
- bispecific PSMAxCD3 antibody CC-1
02
Targets
PSMA (Prostate-specific membrane antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on CC-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CC-1.